Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Amgen Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (89)
Cancellation by sponsor (39)
Australian public assessment report (AusPar) (19)
Prescription medicine registration (17)
Designation or determination (8)
Prescription medicine decision summary (3)

Date

2025 (16)
2024 (28)
2023 (19)
2022 (11)
2021 (7)
2020 (6)
2019 (12)
2018 (8)
2017 (4)
2016 (4)
2015 (10)
2014 (2)
2012 (1)
2011 (3)
2010 (14)
2008 (4)
2006 (13)
2002 (1)
2001 (12)

Search

Sponsor content

175 result(s) found, displaying 31 to 40

AusPAR: Kyprolis

24 September 2024

Australian public assessment report (AusPar)

Kyprolis (carfilzomib) was approved to treat relapsed or refractory multiple myeloma.
RISTEMPA pegfilgrastim (rbe) 6mg/0.6mL injection syringe with automatic needle guard Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEULASTA pegfilgrastim (rbe) 6mg/0.6mL injection syringe with automatic needle guard Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEULASTA pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEUPOGEN filgrastim (rbe) 480 microgram/0.5mL injection syringe Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEUPOGEN filgrastim (rbe) 300 microgram/0.5mL injection syringe Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEUPOGEN filgrastim (rbe) 300 microgram/1mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
NEUPOGEN filgrastim (rbe) 480 microgram/1.6mL injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2024

Cancellation by sponsor

Requested by Amgen Australia Pty Ltd
AusPAR: Wezlana

27 June 2024

Australian public assessment report (AusPar)

Wezlana (ustekinumab) has been approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Notice for Tarlatamab (Amgen Australia Pty Ltd)

22 April 2024

Designation or determination

Provisional determination

Pages

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.